Fig. 1From: Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?Overall survival and progression-free survival curves according to p53 antibody status for the entire population (n = 90)Back to article page